EN DE

Concord Medical Co (6518) Fair Value & Analysis

Healthcare · TW · Market cap 1.0B TWD

CM Concord Medical Co 6518 · TWO
Price31.55 TWD
Fair Value36.28 TWD
Upside+15.0%
Quality70/100
Watch Concord Medical Co for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 7.0% net margin
Low debt · generates free cash flow
4.75% dividend yield
Ranks above peers (13/14)
Narrow moat 42/100
Evidence: High Range 26.45 TWD – 46.11 TWD Share as image

Fair value as of: Jul 23, 2026

From 26 valuation models · updated 18 days ago

Share price −0.5% over the past month.

A solid business, screening 15% undervalued on our models.

What matters now

  • Our model range runs from 26.45 TWD (bear) to 46.11 TWD (bull), base 36.28 TWD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 70/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

52.10 TWD 9.75 TWD Fair Value 36.28 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 9.75 TWD – 52.10 TWD · fair‑value band 26.45 TWD – 46.11 TWD · the 31.55 TWD price screens below the 36.28 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Concord Medical Co (6518) currently trades at 31.55 TWD, while our model-based Fair Value estimate is 36.28 TWD, implying the stock looks roughly 15.0% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Concord Medical Co generated revenue of 964M TWD at a net margin of 7.0%. Revenue grew 12.9% year over year. It earns a return on equity of 9.4%. Net debt stands at 101M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 26.45 TWD (bear case) to 46.11 TWD (bull case); at 31.55 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 36% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 15%, 6518 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 37.70 TWD 49.82 TWD 64.65 TWD 80
Residual Income 17.80 TWD 19.12 TWD 21.24 TWD 76
Rev-Margin DCF 28.53 TWD 39.70 TWD 52.39 TWD 74
All 26 models by family
DCF Models
FCF DCF 37.35 TWD 51.08 TWD 68.88 TWD 38
Owner Earnings 36.00 TWD 49.17 TWD 66.26 TWD 31
5Y Revenue Exit 28.53 TWD 39.23 TWD 52.34 TWD 39
5Y EBITDA Exit 41.51 TWD 63.05 TWD 87.62 TWD 41
5Y P/E Exit 33.24 TWD 47.88 TWD 62.76 TWD 38
10Y Revenue Exit 31.38 TWD 41.32 TWD 53.68 TWD 36
10Y EBITDA Exit 39.39 TWD 56.27 TWD 77.83 TWD 37
10Y P/E Exit 34.60 TWD 46.74 TWD 60.81 TWD 35
Earnings-Based
Graham-Dodd 13.74 TWD 38.85 TWD 51.15 TWD 54
Lynch FV 7.89 TWD 11.28 TWD 14.66 TWD 50
PEG = 1.0 7.89 TWD 11.28 TWD 14.66 TWD 46
EPV 18.14 TWD 20.10 TWD 21.73 TWD 59
Dividend Discount
Gordon GGM 8.55 TWD 15.40 TWD 21.20 TWD 70
DDM Multi-Stage 8.55 TWD 12.77 TWD 16.45 TWD 61
Multiples
P/E Multiple 30.31 TWD 40.42 TWD 50.52 TWD 63
P/S Multiple 25.77 TWD 34.36 TWD 42.94 TWD 58
P/B Multiple 25.77 TWD 34.36 TWD 42.94 TWD 55
EV/EBIT 33.24 TWD 43.07 TWD 52.90 TWD 53
EV/EBITDA 49.90 TWD 65.29 TWD 80.67 TWD 54
EV/Revenue 23.63 TWD 32.15 TWD 40.67 TWD 43
Asset-Based
NCAV (Graham) 10.92 TWD 14.63 TWD 21.84 TWD 50
Growth DCF
Growth DCF 37.70 TWD 49.82 TWD 64.65 TWD 80
Rev-Margin DCF 28.53 TWD 39.70 TWD 52.39 TWD 74
Economic Profit
Residual Income 17.80 TWD 19.12 TWD 21.24 TWD 76
ROIC Compounder 18.14 TWD 20.10 TWD 21.73 TWD 72
Growth Earnings
Growth-Adj P/E 24.38 TWD 34.83 TWD 45.28 TWD 68

Widest divergence: DCF Models (47.88 TWD) versus Earnings-Based (11.28 TWD). Highest evidence: Growth DCF (80).

Notify me when 6518 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 964M TWD
Revenue growth (YoY) +12.9%
Net margin 7.0%
Return on equity 9.4%
Free cash flow 122M TWD FY2025
P/E ratio 15.7
More key figures
Operating margin 7.2%
EPS (TTM) 2.01 TWD
Dividend yield 4.8%
EPS growth (YoY) +48.0%
Net debt 101M TWD FY2024

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 70/100

Of which business quality 69 · Market factors (momentum, volatility) 53

Profitability 40
Margins and returns on capital today
Quality Growth 58
Are margins and returns improving?
Cashflow 73
Earnings quality: real cash, not paper profit
Fin. Strength 83
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 59
Price trend over the last 3–12 months (market factor)
52W Momentum 46
Distance to the 52-week high (market factor)
Net Issuance 83
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Concord Medical Co., Ltd. provides hospital management support services primarily in Taiwan. The company offers medical management services that include medical training and nursing staffing and assisting on medical management; and procurement services for instruments and equipment, drugs, medical materials and consumables, testing equipment, and reagents …

Full company description

Concord Medical Co., Ltd. provides hospital management support services primarily in Taiwan. The company offers medical management services that include medical training and nursing staffing and assisting on medical management; and procurement services for instruments and equipment, drugs, medical materials and consumables, testing equipment, and reagents and consumables, as well as develops its own brand for medical aesthetic skincare products, health foods, and topical Chinese medicine products. It is also involved in the medical equipment planning and sales; and medical equipment leasing activities. The company was founded in 2009 and is headquartered in New Taipei City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Concord Medical Co reported revenue of 964M TWD in FY2025 versus 739M TWD in FY2021, a compound +6.9%/yr. Reported net income was 67.4M TWD in FY2025, compounding +18.3%/yr from FY2021.

Growth Quality 65/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
964M TWD
Latest YoY
+8.4%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+2.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.6%
Avg. growth/yr (6Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.0%
Revenue +6.9%/yr
FY21 739M TWD
FY22 889M TWD
FY23 833M TWD
FY24 890M TWD
FY25 964M TWD
Net income +18.3%/yr
FY21 34.4M TWD
FY22 50.7M TWD
FY23 42.7M TWD
FY24 49.6M TWD
FY25 67.4M TWD

Watch 6518: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Concord Medical Co Fair Value". https://www.fairvalue-calculator.com/stock/6518

Peer Group

Medical Instruments & Supplies · 203 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 70 · Top 25%
Fair Value upside +15% · Top 25%
Return on equity (TTM) 9% · Above median
Return on assets 4% · Above median
Net margin (TTM) 7% · Above median
Operating margin (TTM) 7% · Below median
Revenue growth 13% · Above median
Dividend yield (TTM) 4.8% · Top 25%

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 15.7× · Cheaper than median
P/B 1.44× · Cheaper than median
P/S (TTM) 1.09× · Cheaper than median
P/FCF 0.3× · Cheaper than 75% of peers
EV/EBITDA 7.2× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 53 · sector 0
FUTURE 65 · sector 27
PAST 37 · sector 25
HEALTH 100 · sector 96
DIVIDEND 95 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.33 $150.04 -63%
EssilorLuxottica Société anonyme 1EL €172.45 €68.55 -60%
Medline Inc MDLN $41.11 $30.15 -27%
Becton, Dickinson and Company BDX $150.65 $103.53 -31%
Alcon Inc ALC $70.26 $39.78 -43%
ResMed Inc RMD $203.87 $187.89 -8%
West Pharmaceutical Services, Inc WST $353.71 $143.97 -59%
Straumann Holding STMN CHF 106.00 CHF 47.31 -55%
Sartorius Stedim Biotech S.A DIM €188.50 €51.16 -73%
Coloplast A/S COLOB kr 414.00 kr 382.22 -8%

Compare Concord Medical Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Concord Medical Co (6518) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 36.28 TWD versus a price of 31.55 TWD, about +15% (undervalued).
What is the fair value of 6518?
Our model-based fair value for Concord Medical Co is 36.28 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 31.55 TWD.
What is the quality score of 6518?
Concord Medical Co has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Concord Medical Co (6518)?
Concord Medical Co reported trailing-twelve-month revenue of about 964M TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 6518?
The net profit margin of Concord Medical Co is about 7.0%, meaning it keeps roughly 7.0% of revenue as net income. Based on the latest reported figures.
Does Concord Medical Co pay a dividend?
Concord Medical Co currently shows a dividend yield of about 5.19% relative to its recent price (as of Jul 23, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Concord Medical Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.